Carsten Hjorthøj1, Allan Fohlmann, Merete Nordentoft. 1. Psychiatric Center Bispebjerg, Faculty of Health Sciences, Copenhagen University: Bispebjerg Bakke 23, building 13A, DK-2400 Copenhagen NV, Denmark. carsten@capopus.dk
Abstract
BACKGROUND: Cannabis use disorders (CUD) are prevalent among people with schizophrenia spectrum disorders (SSD), with a range of detrimental effects, e.g. reduced compliance to medication and psychosocial interventions, and increased level of psychotic-dimension symptoms. The aim of this study was to review literature on treatments of CUD in SSD-patients. METHODS: PubMed, PsycINFO, EMBASE, and The Cochrane Central Register of Controlled Trials were searched. RESULTS: 41 articles were selected, 11 treating cannabis as a separate outcome. Contingency management was only effective while active. Pharmacological interventions appeared effective, but lacked randomized controlled trials (RCTs). Psychosocial interventions, e.g. motivational interviewing and cognitive behavior therapy (CBT), were ineffective in most studies with cannabis as a separate outcome, but effective in studies that grouped cannabis together with other substance use disorders. CONCLUSIONS: Insufficient evidence exists on treating this form of dual-diagnosis patients. Studies grouping several types of substances as a single outcome may overlook differential effects. Future RCTs should investigate combinations of psychosocial, pharmacological, and contingency management.
BACKGROUND: Cannabis use disorders (CUD) are prevalent among people with schizophrenia spectrum disorders (SSD), with a range of detrimental effects, e.g. reduced compliance to medication and psychosocial interventions, and increased level of psychotic-dimension symptoms. The aim of this study was to review literature on treatments of CUD in SSD-patients. METHODS: PubMed, PsycINFO, EMBASE, and The Cochrane Central Register of Controlled Trials were searched. RESULTS: 41 articles were selected, 11 treating cannabis as a separate outcome. Contingency management was only effective while active. Pharmacological interventions appeared effective, but lacked randomized controlled trials (RCTs). Psychosocial interventions, e.g. motivational interviewing and cognitive behavior therapy (CBT), were ineffective in most studies with cannabis as a separate outcome, but effective in studies that grouped cannabis together with other substance use disorders. CONCLUSIONS: Insufficient evidence exists on treating this form of dual-diagnosis patients. Studies grouping several types of substances as a single outcome may overlook differential effects. Future RCTs should investigate combinations of psychosocial, pharmacological, and contingency management.
Authors: Gilles Fleury; Robert Milin; David Crockford; Leslie Buckley; Dara Charney; Tony P George; Nady el-Guebaly Journal: Can J Psychiatry Date: 2015-12 Impact factor: 4.356
Authors: Adina S Fischer; Susan Whitfield-Gabrieli; Robert M Roth; Mary F Brunette; Alan I Green Journal: Schizophr Res Date: 2014-07-16 Impact factor: 4.939
Authors: Karolina Kozak Bidzinski; Darby J E Lowe; Marcos Sanches; Maryam Sorkhou; Isabelle Boileau; Michael Kiang; Daniel M Blumberger; Gary Remington; Clement Ma; David J Castle; Rachel A Rabin; Tony P George Journal: Schizophrenia (Heidelb) Date: 2022-02-24
Authors: Helen Frost; Pauline Campbell; Margaret Maxwell; Ronan E O'Carroll; Stephan U Dombrowski; Brian Williams; Helen Cheyne; Emma Coles; Alex Pollock Journal: PLoS One Date: 2018-10-18 Impact factor: 3.240